Navigation Links
Sanford-Burnham research advances to patient studies at TRI

ORLANDO, Fla., March 6, 2012 Discoveries made in the laboratories of Sanford-Burnham Medical Research Institute at Lake Nona will, for the first time, advance to the clinical research stage involving human studies at the Florida Hospital Sanford-Burnham Translational Research Institute for Metabolism and Diabetes (TRI). The research will focus on orexin, an appetite-inducing hormone produced in the brain, which appears to resolve obesity without changes in food consumption or elevation in physical activity. This research is an example of the translational research focus at Sanford-Burnham and the TRI advancing science from laboratory bench to patient bedside. The studies will provide insight into individual responses and contribute to the development of personalized therapies for treating metabolic diseases - a focus area for both TRI and Sanford-Burnham.

Appetite-suppressing drugs have traditionally been the basis of weight-loss treatments since obesity is thought to be caused by excessive energy intake and low physical activity. However, appetite suppressants can produce unacceptable side effects and, after the treatment ends, patients usually regain more weight than they lost. Recent data indicate that orexin leads to weight loss by releasing excess energy as heat instead of storing it.

"At the center of our study," said Devanjan Sikder, D.V.M., Ph.D., assistant professor in Sanford-Burnham's Diabetes and Obesity Research Center, "is an anti-obesity strategy that does not rely on reducing food intake. Instead, we focus on the energy expenditure and feeding-inducing properties of orexin." He added, "My team has discovered that orexin activates calorie-burning brown fat, which we consider to be 'good' fat, and evidence strongly suggests that human obesity can arise from brown fat dysfunction."

Brown fat burns high quantities of sugar and fat, a process that is designed by nature to moderate body temperature in babies, who have large numbers of brown fat cells. By finding a way to activate brown fat in adults, calories, which otherwise would be stored as unwanted white fat, can be burned. Orexin deficiency is associated with obesity in both animals and humans, while high orexin levels correlate with leanness.

"Advancing this orexin research to the TRI is a crucial first step in translating fundamental research at Sanford-Burnham to the clinical phase," said Steven Smith, M.D., scientific director of the TRI and co-director of translational research for Sanford-Burnham's Diabetes and Obesity Research Center. "At the TRI we will conduct proof-of-concept experiments to validate this new drug target and begin to test it for safety and efficacy."

So far, orexin has only been tested in mouse models, where it has been shown to reduce fat by 50 percent, even under conditions of caloric excess. The fat loss is due to an elevation in the metabolic rate. During the study at the TRI, scientists will conduct clinical testing to assess orexin's mode of action, efficacy, and how it works in the human body, as well as evaluate the hormone's acute effect in stimulating energy expenditure.

When it opens in March 2012, the TRI's new 54,000 sq. ft. facility in Orlando, Florida, will contain a research clinic, imaging technology, a biorepository for sample collection and storage, as well as several other resources for metabolic studies. But the facility's highlight will be the calorimeter rooms - small dormitory-style rooms that will allow TRI staff to measure fat and carbohydrate oxidation and energy expenditure as a person goes about his or her normal life. To make the best use of the generated data, the TRI is also building a superior informatics platform to collect and analyze their own research data, as well as personal and sample information for thousands of Florida Hospital patients. This database will help TRI, Florida Hospital and Sanford-Burnham scientists to better correlate patient information with data collected through laboratory research in Sanford-Burnham's metabolomics laboratory.


Contact: Deborah Robison
Sanford-Burnham Medical Research Institute

Related medicine news :

1. Sanford-Burnham and Florida Hospital review obesity research progress with Takeda Pharmaceutical
2. Moffitt, Sanford-Burnham and Florida Hospital create Personalized Medicine Partnership of Florida
3. Sanford-Burnham researchers find molecular switch that allows melanoma to resist therapy
4. Scripps Health and Sanford-Burnham to collaborate to advance new cancer treatments
5. Dr. Kristiina Vuori Promoted to President of Sanford-Burnham Medical Research Institute
6. Dana-Farber and Sanford-Burnham Institute license flu-targeting antibodies to Genentech and Roche
7. Chinese Minister of Health to hold US meeting to improve cancer research collaboration
8. Researchers ID gene behind primary cervical dystonia, a neck-twisting disorder
9. Notre Dames Bengal Bouts participants aid in concussion research
10. NIH asthma outcome measures aim to maximize research investments, reduce disparities
11. Standardized outcome measures proposed for asthma clinical research
Post Your Comments:
(Date:6/25/2016)... , ... June 25, 2016 , ... First Choice ... States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm ... Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van Mitchell, ... at Work award to iHire in recognition of their exemplary accomplishments in worksite health ... annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. ...
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set ... drug or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, ... traumatic event. , Trauma sufferers tend to feel a range of emotions, from depression, ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association ... it will receive two significant new grants to support its work to advance ... 25th anniversary by recognizing patients, medical professionals and scientists for their work in ...
(Date:6/24/2016)... ... 2016 , ... Comfort Keepers® of San Diego, CA is excited to announce ... program to drive cancer patients to and from their cancer treatments. Comfort Keepers ... of life and ongoing independence. Getting to and from medical treatments is one ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... -- Research and Markets has announced the addition ... to their offering. The ... commercial environment for MedImmune to enter. The US ageing population ... to drive considerable growth for effective anti-influenza medications. The introduction ... considerably, but development is still in its infancy. ...
(Date:6/23/2016)... and INDIANAPOLIS , June 23, 2016 ... Lilly Diabetes Tomorrow,s Leaders Scholarship is any indication, the ... announced today online at by the ... diabetes stand in the way of academic and community ... Foundation,s scholarship program since 2012, and continues to advocate ...
(Date:6/23/2016)...  Guerbet announced today that it has been named ... . One of 12 suppliers to receive ... support of Premier members through exceptional local customer service ... to lower costs. ... outstanding customer service from Premier," says Massimo Carrara ...
Breaking Medicine Technology: